Trial Profile
Phase II trial on Programmed death-One inhibitor plus RadioThERapy in patients with Metastatic Mucosal Melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PORTER-M3 trial
- 14 Sep 2018 Status changed from not yet recruiting to recruiting.
- 05 Mar 2018 New trial record